These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18763714)

  • 1. Design of potent aspartic protease inhibitors to treat various diseases.
    Nguyen JT; Hamada Y; Kimura T; Kiso Y
    Arch Pharm (Weinheim); 2008 Sep; 341(9):523-35. PubMed ID: 18763714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
    Maegawa H; Kimura T; Arii Y; Matsui Y; Kasai S; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5925-9. PubMed ID: 15501070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
    Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.
    Blum A; Böttcher J; Sammet B; Luksch T; Heine A; Klebe G; Diederich WE
    Bioorg Med Chem; 2008 Sep; 16(18):8574-86. PubMed ID: 18760609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.
    Wångsell F; Russo F; Sävmarker J; Rosenquist A; Samuelsson B; Larhed M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4711-4. PubMed ID: 19576765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors.
    Wångsell F; Nordeman P; Sävmarker J; Emanuelsson R; Jansson K; Lindberg J; Rosenquist S; Samuelsson B; Larhed M
    Bioorg Med Chem; 2011 Jan; 19(1):145-55. PubMed ID: 21183353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
    Hoegl L; Korting HC; Klebe G
    Pharmazie; 1999 May; 54(5):319-29. PubMed ID: 10368824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.
    Kimura T; Shuto D; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Hattori C; Asai M; Kitazume S; Saido TC; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1527-31. PubMed ID: 15006396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase.
    Hom RK; Gailunas AF; Mamo S; Fang LY; Tung JS; Walker DE; Davis D; Thorsett ED; Jewett NE; Moon JB; John V
    J Med Chem; 2004 Jan; 47(1):158-64. PubMed ID: 14695829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.
    Park H; Lee S
    J Am Chem Soc; 2003 Dec; 125(52):16416-22. PubMed ID: 14692784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.
    Kimura T; Shuto D; Hamada Y; Igawa N; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2005 Jan; 15(1):211-5. PubMed ID: 15582441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Jacobsen S; Magolda RL; Pangalos M; Robichaud AJ
    J Med Chem; 2010 Feb; 53(3):1146-58. PubMed ID: 19968289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of potent inhibitors of human beta-secretase. Part 1.
    Freskos JN; Fobian YM; Benson TE; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Moon JB; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
    Bioorg Med Chem Lett; 2007 Jan; 17(1):73-7. PubMed ID: 17046251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
    Lindsley SR; Moore KP; Rajapakse HA; Selnick HG; Young MB; Zhu H; Munshi S; Kuo L; McGaughey GB; Colussi D; Crouthamel MC; Lai MT; Pietrak B; Price EA; Sankaranarayanan S; Simon AJ; Seabrook GR; Hazuda DJ; Pudvah NT; Hochman JH; Graham SL; Vacca JP; Nantermet PG
    Bioorg Med Chem Lett; 2007 Jul; 17(14):4057-61. PubMed ID: 17482814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
    Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protease inhibitors].
    Hamada Y; Kiso Y
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1702-7. PubMed ID: 18051403
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues.
    Bäck M; Nyhlén J; Kvarnström I; Appelgren S; Borkakoti N; Jansson K; Lindberg J; Nyström S; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2008 Nov; 16(21):9471-86. PubMed ID: 18842420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.
    Huang Y; Strobel ED; Ho CY; Reynolds CH; Conway KA; Piesvaux JA; Brenneman DE; Yohrling GJ; Moore Arnold H; Rosenthal D; Alexander RS; Tounge BA; Mercken M; Vandermeeren M; Parker MH; Reitz AB; Baxter EW
    Bioorg Med Chem Lett; 2010 May; 20(10):3158-60. PubMed ID: 20399652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors.
    Tagad HD; Hamada Y; Nguyen JT; Hidaka K; Hamada T; Sohma Y; Kimura T; Kiso Y
    Bioorg Med Chem; 2011 Sep; 19(17):5238-46. PubMed ID: 21803585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.